Fig. 5

CSMD1 sensitized glioma cells to chemotherapy treatment but TNF did not increase the chemoresistance. A H4, B U-118 and C U-87 cells were treated with TNF (25 ng/ml), temozolomide (500 µM) and/or lomustine (50 µM) for 48 h. BSA, DMSO or BSA + DMSO treated cells were used as negative controls for normalization. High expression of CSMD1 was associated with an increased response to temozolomide treatment in (D) mutated IDH (n = 87), E wild-type IDH (n = 102), F co-deleted 1p/19q (n = 31) and G non-co-deleted 1p/19q (n = 154) glioma samples. A two-way ANOVA Bonferroni’s multiple comparisons test was used when comparing 3 or more groups with 2 variables (* < 0.05, ** < 0.01, **** < 0.0001). Long-rank (Mantel-Cox) test was used for survival curves